Stocks once again are oscillating between slim gains and losses
ahead of the release of minutes from the last meeting of the
Federal Open Markets Committee meeting and the yearly meeting of
central bankers in Jackson Hole, Wyo., later in the week. Stocks
are also hamstrung by rising Treasury yields, with traders worried
the higher financing costs will stifle economic growth and
liquidity. The 10-year note is currently trading at yet another 2
European markets are trading lockstep with their U.S.
counterparts with most of the regional indices ending in the red.
The dearth of economic news out of the euro-zone also is
contributing to the listless tone with little on the EU economic
calendar until at least Wednesday.
Crude oil was up $0.24 to $107.70 per barrel. Natural gas was up
$0.12 to $3.63 per 1 million BTU. Gold was down $4.00 to $1,367.00
an ounce, while silver was down $0.20 to $23.18 an ounce. Copper
was down $0.03 to $3.34 per pound.
, the United States Oil Fund was down 0.21% to $38.32 with the
United States Natural Gas Fund was up $0.60 to $18.46. Amongst
precious-metal funds, the Market Vectors Gold Miners ETF was down
0.95% to 29.67 while SPDR Gold Shares were down 0.44% to $131.99.
The iShares Silver Trust was down 0.09% to $22.32%.
Here's where the U.S. markets stand at mid-day:
NYSE Composite Index down 33.47 (-0.35%) to 9,432.12
Dow Jones Industrial Average down 16.43 (-0.11%) to
S&P 500 down 1.70 (-0.10%) to 1,654.13
Nasdaq Composite Index up 14.31 (+0.40%) to 3,617.09
Nikkei 225 Index up 0.79%
Hang Seng Index down 0.24%
Shanghai China Composite Index up 0.83%
FTSE 100 Index down 0.53%
CAC 40 down 0.97%
DAX down -0.31%
NYSE SECTOR INDICES
NYSE Energy Sector Index down 0.68%
NYSE Financial Sector Index down 0.73%
NYSE Healthcare Sector Index up 0.36%
(+) EVAC (+18.11%) Agrees to $1.6-billion buyout offer from
Atlas Copco Group.
(+) SUPN (+12.47%) The company's epilepsy drug gets FDA
(+) P (+5.95%) Needham & Co. raises price target for the
stock to $25
(-) Z (-4.36%) Launches underwritten stock offering of 5 million
shares, including 2.5 mln shares sold by the company.
(-) TRLA (-4.00%) RBC downgrades the stock to Sector Perform
(-) GTXI (-63.61%) Clinical trials for prospective lung-cancer
drug fails to meet co-primary endpoints
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.